Regulations governing adverse event reporting and manufacturing facility registration must be reviewed and potentially updated by the US Food and Drug Administration or face rescission.
The Health and Human Services Department on 8 January announced that it will finalize a proposed rule requiring many regulations to be regularly assessed to determine whether they remain relevant and need updating. Under the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?